Diwakar Davar

Associate Professor of Medicine; Clinical Director, Melanoma and Skin Cancer Program; Associate Chief, Academic Affairs

UPMC Hillman Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Diwakar Davar is an Associate Professor of Medicine at Hillman Cancer Center at UPMC, located in the United States. He serves as the Clinical Director of the Melanoma and Skin Cancer Program and holds the position of Associate Chief for Academic Affairs. His research focuses on immunotherapy for cancer, particularly in the areas of PD-1, TIM-3, and LAG-3 targeting, as well as biomarkers for immune checkpoint blockade in various malignancies.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (4)

Ludimila Cavalcante

Associate Professor, Director, Sarcoma Medical Oncology, Associate Director, Developmental Therapeutics

University of Virginia

UNITED STATES

View details

Samuel McBrayer

Assistant Professor

University of Texas Southwestern Department of Pediatrics

UNITED STATES

View details

Kalil G Abdullah

University of Pittsburgh Medical Center

UNITED STATES

View details

Ana Anderson

Associate Professor

Brigham and Women's Hospital

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Diwakar Davar

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A

Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B

Therapeutic potential of targeting LAG-3 in cancer

There and back again: PD-L1 Positivity as a Biomarker for Immune Checkpoint Blockade in Urothelial Carcinoma

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)

Matched three-dimensional organoids and two-dimensional cell lines of melanoma brain metastases mirror response to targeted molecular therapy

Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial

Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors

Immunomodulatory Effects of RANK/RANKL Blockade in Patients with Cancer

Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease

Collaborators (4)

Ludimila Cavalcante

Samuel McBrayer

Kalil G Abdullah

Ana Anderson

Make your next move.